Bronchopulmonary dysplasia (BPD) is a lung complication of premature births. The leading
causes of BPD are oxidative stress (OS) from oxygen treatment, infection or inflammation …

Coronary artery disease (CAD) and myocardial infarction (MI) remain leading causes of
death and disability worldwide. CAD begins with the formation of atherosclerotic plaques …

Aims Mitiperstat (formerly AZD4831) is a novel selective myeloperoxidase inhibitor.
Currently, no effective therapies target comorbidity‐induced systemic inflammation, which …

Background Inflammation is a key driver of heart failure with preserved left ventricular
ejection fraction. AZD4831 inhibits extracellular myeloperoxidase, decreases inflammation …

Currently there are no established therapies to treat high-risk patients with unstable
atherosclerotic lesions that are prone to rupture and can result in thrombosis, abrupt arterial …

Myocardial infarction (MI) is a leading cause of morbidity and mortality worldwide. Improved
survival has led to an increasing incidence of ischemic cardiomyopathy, making it a major …

Functioning as a surrogate for step count, a cumulative complexity meta-metric (∑ CM*),
calculated along the longest linear sequence of a synthetic route, is demonstrated to be a …

Pancreatic ductal adenocarcinoma is a devastating disease characterized by an extreme
resistance to current therapies, including immune checkpoint therapy. The limited success of …

We report herein an in-depth analysis of the metabolism of the novel myeloperoxidase
inhibitor AZD4831 ((R)-1-(2-(1-aminoethyl)-4-chlorobenzyl)-2-thioxo-2, 3-dihydro-1H-pyrrolo …

Background The detection of unstable atherosclerosis remains elusive. Intraplaque
myeloperoxidase (MPO) activity causes plaque destabilization in preclinical models, holding …